Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

373
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
373
Evolutionary Relationships through Genome Comparisons02:54

Evolutionary Relationships through Genome Comparisons

6.6K
Genome comparison is one of the excellent ways to interpret the evolutionary relationships between organisms. The basic principle of genome comparison is that if two species share a common feature, it is likely encoded by the DNA sequence conserved between both species. The advent of genome sequencing technologies in the late 20th century enabled scientists to understand the concept of conservation of domains between species and helped them to deduce evolutionary relationships across diverse...
6.6K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

394
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
394

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for Genetics.

Clinical genetics·2026
Same author

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

The Journal of experimental medicine·2026
Same author

The WHO Classification of Genetic Tumour Syndromes: Considerations for histopathology.

Histopathology·2026
Same author

Reversing-or Rewiring-Lineage Plasticity? Lessons from EZH2 Loss in Prostate Cancer.

Cancer research·2026
Same author

A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.

Cancer research·2026
Same journal

On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

The Journal of urology·2026
Same journal

Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

The Journal of urology·2026
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

The Journal of urology·2026
Same journal

Let's Shift the Focus from Death to Life after Fournier's Gangrene.

The Journal of urology·2026
Same journal

Endourology and Nephrolithiasis.

The Journal of urology·2026
See all related articles

Related Experiment Videos

Using molecular markers to predict outcome.

Mark A Rubin1

  • 1Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. marubin@partners.org

The Journal of Urology
|November 13, 2004
PubMed
Summary
This summary is machine-generated.

Developing molecular tests for prostate cancer progression requires defining clinical endpoints and leveraging new technologies. Advances in high-throughput methods are accelerating biomarker discovery for better monitoring.

Related Experiment Videos

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Medical Technology

Background:

  • Prostate cancer progression prediction is crucial for effective treatment.
  • Current methods for monitoring disease spread are limited.
  • Defining clear clinical endpoints is essential for developing predictive molecular tests.

Purpose of the Study:

  • To review strategies for developing molecular tests to predict prostate cancer progression.
  • To explore the role of emerging technologies in this field.
  • To address the need for meaningful clinical endpoints in prostate cancer research.

Main Methods:

  • Literature review of clinical trials, nomograms, and biomarker development.
  • Analysis of high-throughput technologies for gene and biomarker identification.
  • Examination of current imaging techniques and their limitations.

Main Results:

  • Controversy exists regarding the utility of PSA or biochemical failure as progression markers.
  • High-throughput technologies (expression arrays, proteomics, bioinformatics) accelerate candidate biomarker discovery.
  • Novel biomarkers could enable in vivo monitoring of prostate cancer, a significant advancement.

Conclusions:

  • Emerging technologies offer the potential to analyze clinical trials with adequate follow-up.
  • This analysis will aid in developing meaningful markers for prostate cancer progression.
  • Future work focusing on novel biomarkers may revolutionize disease monitoring.